Westbury, NY 7/9/18—BioIVT, which provides research models and services, has acquired Optivia Biotechnology for an undisclosed amount. Optivia Biotechnology specializes in transport protein assays and services for drug research. “We are delighted that Optivia is joining BioIVT as we position to become the world leader in transporter sciences,” stated BioIVT CEO Jeffrey Gatz. “Optivia will be an important addition to BioIVT’s leading ADME-Toxicology model systems franchise, complementing the capabilities of our recent acquisitions of Qualyst Transporter Solutions and Ascendance Biotechnology.” Optivia will become part of BioIVT’s PHASEZERO Research Services business.

 Including Optiva Biotechnology, BioIVT has steadily expanded from a supplier of biological specimens to products such as cell culture media and stem cells, as well as services, having acquired three firms since March 2017 (TransCell Science, Ascendance Biotechnology, Qualyst Transporter Solutions). Optiva Biotechnology’s commercial products include the TransFlex transporter plates.